271 related articles for article (PubMed ID: 29802706)
1. Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis.
Liang ZG; Lin GX; Ye JX; Li Y; Li L; Qu S; Liang X; Zhu XD
Asian Pac J Cancer Prev; 2018 May; 19(5):1397-1404. PubMed ID: 29802706
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
5. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma.
Wang BC; Shi LL; Fu C; Zhou HX; Zhang ZJ; Ding Q; Peng G
Medicine (Baltimore); 2019 Oct; 98(42):e17486. PubMed ID: 31626102
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
[TBL] [Abstract][Full Text] [Related]
8. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
Cancer Sci; 2018 May; 109(5):1609-1616. PubMed ID: 29575438
[TBL] [Abstract][Full Text] [Related]
9. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: meta-analysis of 1,096 patients from 11 randomized controlled trials.
Liang ZG; Zhu XD; Tan AH; Jiang YM; Qu S; Su F; Xu GZ
Asian Pac J Cancer Prev; 2013; 14(1):515-21. PubMed ID: 23534786
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Ma BBY; Kam MKM; Leung SF; Hui EP; King AD; Chan SL; Mo F; Loong H; Yu BKH; Ahuja A; Chan ATC
Ann Oncol; 2012 May; 23(5):1287-1292. PubMed ID: 21948811
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
Wang L; Liu D; Wei D
Comput Math Methods Med; 2022; 2022():5145549. PubMed ID: 36060662
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials.
Du CR; Ying HM; Kong FF; Zhai RP; Hu CS
Radiat Oncol; 2015 Mar; 10():70. PubMed ID: 25889937
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
Lee AWM; Tung SY; Ng WT; Lee V; Ngan RKC; Choi HCW; Chan LLK; Siu LL; Ng AWY; Leung TW; Yiu HHY; O'Sullivan B; Chappell R
Cancer; 2017 Nov; 123(21):4147-4157. PubMed ID: 28662313
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
[TBL] [Abstract][Full Text] [Related]
18. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
[TBL] [Abstract][Full Text] [Related]
19. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.
Yuan JJ; Ding JW; Li JW; Hu RH; Gong D; Hu JL; Zhu KB; Liu Y; Ding YH; Wei JW; Zeng JL; Lu ZB; Yin WH; Ai SF; Zha GH; Zhang ZL; Zou R; Zeng L
BMJ Open; 2022 Aug; 12(8):e051594. PubMed ID: 36008072
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
Huang JF; Zhang FZ; Zou QZ; Zhou LY; Yang B; Chu JJ; Yu JH; Zhang HW; Yuan XP; Tai GM; Liu FJ; Ma CC
Oncotarget; 2017 Jan; 8(2):2457-2465. PubMed ID: 27974693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
